Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 5 Colorectal Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Neoplasms 3 Lung Neoplasms 3 Solid Tumors 1 Rectal Neoplasms 1 Pleural Effusion 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neuroendocrine Tumors 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Insulin-Like Growth Factor I, Resistance To 1 Fallopian Tube Neoplasms 1 Advanced Solid Tumors 1 Adenocarcinoma 1

Interventions

Oxaliplatin 271 Fluorouracil 268 Capecitabine 235 Leucovorin 209 Irinotecan 152 Radiotherapy 139 Bevacizumab 114 Cetuximab 82 Surgical Procedures, Operative 51 Folfox protocol 49 Neoadjuvant Therapy 45 Drug Therapy 43 Radiation 42 Chemotherapy, Adjuvant 34 Chemoradiotherapy 34 Panitumumab 27 Magnetic Resonance Spectroscopy 26 XELOX 25 Radiotherapy, Intensity-Modulated 23 Biopsy 20 Surveys and Questionnaires 18 Laparoscopy 18 Proctectomy 17 Floxuridine 17 Early Intervention, Educational 16 Nivolumab 15 Immunohistochemistry 15 Gene Expression Profiling 15 Gemcitabine 15 pembrolizumab 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Rectal Neoplasms × dalotuzumab × Clear all

NCT01609231 2020-05-04

MK-0646-025

Merck Sharp & Dohme LLC

Phase 2 Terminated

11 enrolled 8 charts

Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡